Pulmovant
Pulmovant is seeking a Director of Biostatistics to serve as the lead biostatistician for its Phase 3 PHrontier program evaluating mosliciguat in pulmonary hypertension associated with interstitial lung disease. This role drives the statistical strategy for the pivotal trial, partnering with Clinical Development, Regulatory, and Data Management to ensure rigorous, submission-ready trial design and analysis. The ideal candidate brings direct experience taking a program through Phase 3 and toward regulatory filing.
Pulmovant is a clinical-stage biopharmaceutical company singularly focused on developing innovative inhaled therapies for pulmonary diseases, including pulmonary hypertension. The company's lead candidate, mosliciguat, is a potentially first-in-class once-daily inhaled treatment with a differentiated soluble guanylate cyclase (sGC) activation mechanism. Pulmovant is advancing mosliciguat through clinical trials with the goal of transforming the treatment paradigm for patients with pulmonary diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pulmovant.
Pulmovant didn’t post a salary, so this is our estimate from similar listings.
Pulmovant completes enrollment for PH-ILD treatment trial
1 month ago